Resources

Taiho Oncology
Patient Support

A one-stop source for the
customized support patients need

*Eligible patients may pay $0 per treatment cycle for LONSURF.

See restrictions and eligibility below.

Scroll Down
Dosage

Access & Reimbursement

Designed to simplify patient access to LONSURF

We know getting patients access to LONSURF® (FTD/TPI) tablets is
a critical step in their treatment. We strive to make this process as simple as possible with:

Access and reimbursement support
  • Benefit Verifications (BVs) to determine and report patients' insurance coverage for LONSURF
  • Prior authorization assistance to meet payer requirements
  • Appeals assistance for denied prior authorizations
Specialty pharmacy prescription coordination
  • Prescription triage
  • Coordination with the in‑network specialty pharmacy, self‑dispensing practice, or hospital outpatient pharmacy
  • Communicating regularly with patients about their prescription status
Co‑pay support
  • Eligible, privately insured patients can enroll in the Taiho Oncology Patient Support Co-pay Assistance Program to reduce out-of-pocket expenses for LONSURF to $0

Learn more about the Taiho Oncology Patient Support Co-pay Assistance Program here.

Patient Assistance Program
  • We research financial assistance opportunities for patients with no or insufficient prescription insurance coverage or insufficient resources to pay for LONSURF. Eligible patients may receive LONSURF at no cost based on assistance, financial, and medical criteria
Alternate funding support
  • We refer eligible, publicly insured patients (eg, Medicare, Medicaid) to non-profit foundations for co‑pay assistance
Personalized nurse support upon request
  • Our nurse support services are available as needed to support patient care, including education about the importance of taking the medicine as prescribed and refill reminders. We will quickly verify each patient's LONSURF coverage and help them get access to the LONSURF treatment they have been prescribed

Restrictions and eligibility: Offer valid in the US, Puerto Rico, and US territories only. Only valid for patients with private insurance. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare, or other federal or state programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program, this offer is not valid and the patient cannot use this offer. By presenting or accepting this benefit, patient and pharmacist agree not to submit claim for reimbursement under the above programs. Patient further agrees to comply with any and all terms of his or her health insurance contract requiring notification to his or her payer of the existence and/or value of this offer. It is illegal to or offer to sell, purchase, or trade this benefit. Maximum reimbursement limits apply; patient out-of-pocket expense may vary. Taiho Oncology, Inc., reserves the right to rescind, revoke, or amend this offer at any time without notice.

How to enroll

3 convenient ways to enroll in the Taiho Oncology Patient Support Program:

By Fax

Patient and HCP complete and sign a Patient Enrollment Form and then fax it to 1‑844‑287‑2559.

Online

Patient completes a Patient Enrollment Form online and brings it to the HCP’s office, or HCP completes it electronically.

By Phone

1-844-TAIHO-4U (1-844-824-4648)
for help with enrollment.

Professional Resources & Tools

Dosage Sheet

Reminds patients of their active treatment days and their morning and evening doses. Print a Dosage Sheet and then fill it out with your patient.


LONSURF Overview Brochure

Provides an overview of the safety and efficacy data demonstrated by LONSURF, the importance of dosing for proven results and resources developed to support your patients.


LONSURF Dosage Calculator

Calculate your patients’ personalized dosage and create personalized dosing calendars.


LONSURF: What to Expect

Counselling tips–including possible side effects and health outcomes–to discuss with your patients while they are taking LONSURF.

Patient Resources & Tools

LONSURF Patient Starter Kit

LONSURF Patient Starter Kit

Contains useful resources and tools to help your patients start and stay on LONSURF, including a:

  • Patient Brochure: Offers information on how LONSURF can help, how it is taken, tips on managing common side effects, and services that may be able to help with medication costs
  • Caregiver Brochure: Provides an overview of LONSURF and how it is taken, useful tips that may help manage common side effects, and strategies to help caregivers take care of themselves and their loved one
  • Thermometer: Encourages patients to check for fever while taking LONSURF
  • LONSURF Pillboxes: Designed to help patients organize their LONSURF tablets

To request a Patient Starter Kit, you can:

Ask a representative

Request a representative


Patient Brochure

Offers information on how LONSURF can help, how it is taken, tips on managing common side effects, and services that may be able to help with medication costs.


Caregiver Brochure

Provides an overview of LONSURF and how it is taken, useful tips that may help manage common side effects, and strategies to help caregivers take care of themselves and their loved one.


Side Effect Management Tool

Located on the LONSURF Patient website, this interactive tool outlines useful tips to help patients manage some of the most common side effects associated with LONSURF.


Personalized Treatment Calendar

Located on the LONSURF Patient website, this interactive tool helps you and your patients create a personalized treatment calendar to ensure they understand their dosing schedule.

LONSURF Coding Information

The following 2019 ICD-10 codes are effective from October 1, 2018 through September 30, 2019. The diagnostic codes contained in this section are designed to provide important reimbursement information that will be helpful for your practice. ICD codes continually change, so it is recommended that you consult your ICD-10 code book or contact the payer for coding and billing guidance.

Diagnosis codes for LONSURF® (FTD/TPI) tablets use in metastatic colorectal cancer1

ICD-10-CM Description
C18.0 Malignant neoplasm of cecum
C18.2 Malignant neoplasm of ascending colon
C18.3 Malignant neoplasm of hepatic flexure
C18.4 Malignant neoplasm of transverse colon
C18.5 Malignant neoplasm of splenic flexure
C18.6 Malignant neoplasm of descending colon
C18.7 Malignant neoplasm of sigmoid colon
C18.8 Malignant neoplasm of overlapping sites of colon
C18.9 Malignant neoplasm of colon, unspecified
C19 Malignant neoplasm of rectosigmoid junction
C20 Malignant neoplasm of rectum
C21.8 Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C78.5 Secondary malignant neoplasm of large intestine and rectum
C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum
D37.4 Neoplasm of uncertain behavior of colon
D37.5 Neoplasm of uncertain behavior of rectum

This information is not intended as coverage or coding advice and does not guarantee reimbursement. You should verify the appropriate reimbursement information for services or items you provide. Each healthcare professional is responsible for ensuring all coding is accurate and appropriate.

Diagnosis codes for LONSURF® (FTD/TPI) tablets use in metastatic gastric cancer1

ICD-10-CM Description
C16.0 Malignant neoplasm of cardia
Malignant neoplasm of cardiac orifice
Malignant neoplasm of cardio-esophageal junction
Malignant neoplasm of esophagus and stomach
Malignant neoplasm of gastro-esophageal junction
C16.1 Malignant neoplasm of fundus of stomach
C16.2 Malignant neoplasm of body of stomach
C16.3 Malignant neoplasm of pyloric antrum
Malignant neoplasm of gastric antrum
C16.4 Malignant neoplasm of pylorus
Malignant neoplasm of prepylorus
Malignant neoplasm of pyloric canal
C16.5 Malignant neoplasm of lesser curvature of stomach, unspecified
Malignant neoplasm of lesser curvature of stomach, not classifiable to C16.1-C16.4
C16.6 Malignant neoplasm of greater curvature of stomach, unspecified
Malignant neoplasm of greater curvature of stomach, not classifiable to C16.0-C16.4
C16.8 Malignant neoplasm of overlapping sites of stomach
C16.9 Malignant neoplasm of stomach, unspecified
Gastric cancer NOS

This information is not intended as coverage or coding advice and does not guarantee reimbursement. You should verify the appropriate reimbursement information for services or items you provide. Each healthcare professional is responsible for ensuring all coding is accurate and appropriate.

FTD/TPI = trifluridine/tipiracil

References: 1. ICD-10-CM EXPERT: for Providers & Facilities, AAPC, 2018, p.473-474, 486, 504.

INDICATIONS

INDICATIONS

LONSURF is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine‑, oxaliplatin‑ and irinotecan‑based chemotherapy, an anti‑VEGF biological therapy, and if RAS wild type, an anti‑EGFR therapy.

LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu‑targeted therapy.

Indications and Important Safety Information +

INDICATIONS

LONSURF is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine‑, oxaliplatin‑ and irinotecan‑based chemotherapy, an anti‑VEGF biological therapy, and if RAS wild type, an anti‑EGFR therapy.

LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu‑targeted therapy.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Severe Myelosuppression: LONSURF caused severe and life‑threatening myelosuppression (Grade 3‑4) consisting of neutropenia (38%), anemia (18%), thrombocytopenia (5%), and febrile neutropenia (3%). Two patients (0.2%) died due to neutropenic infection. A total of 12% of LONSURF‑treated patients received granulocyte‑colony stimulating factors. Obtain complete blood counts prior to and on day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for febrile neutropenia, absolute neutrophil count less than 500/mm3, or platelets less than 50,000/mm3. Upon recovery, resume LONSURF at a reduced dose as clinically indicated.

Embryo‑Fetal Toxicity: LONSURF can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 6 months after the final dose.

USE IN SPECIFIC POPULATIONS

Lactation: It is not known whether LONSURF or its metabolites are present in human milk. There are no data to assess the effects of LONSURF or its metabolites on the breast‑fed infant or the effects on milk production. Because of the potential for serious adverse reactions in breast‑fed infants, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose.

Male Contraception: Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose.

Geriatric Use: Patients 65 years of age or over who received LONSURF had a higher incidence of the following compared to patients younger than 65 years: Grade 3 or 4 neutropenia (46% vs 32%), Grade 3 anemia (22% vs 16%), and Grade 3 or 4 thrombocytopenia (7% vs 4%).

Hepatic Impairment: Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin greater than 1.5 times ULN and any AST) hepatic impairment. Patients with severe hepatic impairment (total bilirubin greater than 3 times ULN and any AST) were not studied. No adjustment to the starting dose of LONSURF is recommended for patients with mild hepatic impairment.

Renal Impairment: No adjustment to the starting dosage of LONSURF is recommended in patients with mild or moderate renal impairment (CLcr of 30 to 89 mL/min). Patients with severe renal impairment (CLcr < 30 mL/min) were not studied.

ADVERSE REACTIONS

Most Common Adverse Drug Reactions in Patients Treated With LONSURF (≥5%): The most common adverse drug reactions in LONSURF‑treated patients vs placebo‑treated patients with mCRC, respectively, were asthenia/fatigue (52% vs 35%), nausea (48% vs 24%), decreased appetite (39% vs 29%), diarrhea (32% vs 12%), vomiting (28% vs 14%), infections (27% vs 16%), abdominal pain (21% vs 18%), pyrexia (19% vs 14%), stomatitis (8% vs 6%), dysgeusia (7% vs 2%), and alopecia (7% vs 1%). In metastatic gastric cancer or gastroesophageal junction (GEJ), the most common adverse drug reactions, respectively were, nausea (37% vs 32%), decreased appetite (34% vs 31%), vomiting (25% vs 20%), infections (23% vs 16%) and diarrhea (23% vs 14%).

Pulmonary emboli occurred more frequently in LONSURF‑treated patients compared to placebo: (2% vs 0%) in mCRC and (3% vs 2%) in metastatic gastric cancer and GEJ.

Interstitial lung disease (0.2%), including fatalities, has been reported in clinical studies and clinical practice settings in Asia.

Laboratory Test Abnormalities in Patients Treated With LONSURF: Laboratory test abnormalities in LONSURF‑treated patients vs placebo‑treated patients with mCRC, respectively, were anemia (77% vs 33%), neutropenia (67% vs 1%), and thrombocytopenia (42% vs 8%). In metastatic gastric cancer or GEJ, the test abnormalities, respectively, were neutropenia (66% vs 4%), anemia (63% vs 38%), and thrombocytopenia (34% vs 9%).

Please see full Prescribing Information.